نبذة مختصرة : Background: Renalase is a catecholamine-metabolising enzyme, but its possible association with atrial fibrillation (AF) remains unknown. Aim: We sought to evaluate plasma renalase concentration in patients with AF undergoing pulmonary vein isolation (PVI) with respect to AF clinical characteristics, left atrial (LA) remodelling, and PVI efficacy. Methods: This case-control study included 69 patients (median age 58 years) with either paroxysmal (89%) or persistent (11%) AF, referred for PVI, and a control group consisting of 15 patients without AF, matched for age, sex, and comorbidities. An evaluation of transthoracic echocardiography with LA speckle tracking and plasma renalase concentration using an enzyme-linked immunosorbent assay was performed. AF recurrence was defined as any AF episode on seven-day electrocardiographic monitoring at six-month follow-up. Results: Renalase level was higher in the study group than in the control group (mean 27.99 vs. 21.48 μg/mL, p = 0.004), but it was lower in patients with persistent AF (19.05 vs. 28.77 μg/mL; p = 0.023) and among patients with AF episodes directly preceding PVI (24.50 vs. 29.66 μg/mL; p = 0.04). Renalase concentration within the first quartile was associated with higher mean heart rate (70 vs. 61 bpm, p = 0.029), greater AF burden (36.9% vs. 9.3%, p = 0.027), greater LA diameter (41.1 vs. 37.9 mm, p = 0.011), and a trend towards less negative global LA strain (–9.4 vs. –13.5, p = 0.082). Logistic regression revealed that global four-chamber LA strain was the only independent predictor of renalase variability (p = 0.0045). Renalase concentration did not predict AF recurrence at six-month follow-up (area under curve [AUC] = 0.614, p = 0.216). Conclusions: Low renalase level may be associated with impaired rate control, higher AF burden, and advanced LA remodelling in AF patients undergoing PVI, but it does not predict sinus rhythm maintenance.
Rights: Przesyłając manuskrypt wraz z ilustracjami i tabelami, automatycznie i nieodpłatnie przenosi (przenoszą) na Polskie Towarzystwo Kardiologiczne wszelkie prawa autorskie do wydawania oraz rozpowszechniania nadesłanych materiałów we wszystkich znanych formach i na wszystkich znanych polach eksploatacji, bez ograniczeń terytorialnych językowych pod warunkiem, że materiały te zostaną zaakceptowane do publikacji. ; The copyright to the submitted manuscript is held by the Author, who grants the Polish Cardiac Society a nonexclusive licence to use, reproduce, and distribute the work, including for commercial purposes. Polish Heart Journal (Kardiologia Polska) is an open access journal that applies the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence (CC BY-NC-ND 4.0), allowing third parties to download articles and share them with others, provided the original work is properly cited, not changed in any way, distributed under the same licence, and used for non-commercial purposes only. For commercial use, please contact the journal office: polishheartjournal@ptkardio.pl. If submitted work has been funded by institutional grant, the applicant may optionally choose to release the work under Creative Commons licence: attribution (CC BY) to meet the requirements of funding party, if applicable. Licence Terms can be downloaded here.
Processing Request
No Comments.